Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tildacerfont - Spruce Biosciences

Drug Profile

Tildacerfont - Spruce Biosciences

Alternative Names: SPR 001

Latest Information Update: 10 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Spruce Biosciences
  • Class 2 ring heterocyclic compounds; Morpholines; Pyrazoles; Pyrimidines; Small molecules; Thiazoles
  • Mechanism of Action Corticotropin releasing factor receptor 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital adrenal hyperplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Congenital adrenal hyperplasia; Polycystic ovary syndrome

Most Recent Events

  • 04 Jun 2024 Spruce Biosciences and HMNC Brain Health entered into a strategic collaboration agreement to develop tildacerfont for major depressive disorder
  • 04 Jun 2024 Spruce Biosciences in collaboration with HMNC Brain Health plans a phase II proof-of-concept study of tildacerfont and Cortibon for Major depressive disorder in 2024
  • 03 Jun 2024 Efficacy and adverse event data from the phase II P.O.W.E.R trial in Polycystic ovary syndrome released by Spruce Biosciences
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top